Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2023-11-24 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
薪酬委员会章程
Governance Information Classification · 95% confidence The document is titled '薪酬委員會章程' which translates to 'Compensation Committee Charter'. It details the formation, composition, responsibilities, and procedures of the compensation committee of BeiGene, Ltd. It discusses the committee's role in overseeing executive compensation, preparing reports for inclusion in proxy statements or 10-K annual reports, and other governance-related duties. There is no actual financial data or report content here; rather, it is a governance document outlining internal rules and committee structure related to remuneration. This fits the definition of a Governance Information (CGR) filing, as it details the company's internal governance practices specifically related to the compensation committee. The document length is under 5,000 characters and is not an announcement of a report but the charter itself. Therefore, the appropriate classification is CGR with high confidence.
2023-11-24 Chinese
港股公告：授出购股权及受限制股份单位
Regulatory Filings Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of share options and restricted share units under the 2016 Option and Incentive Plan. It details the number of shares/options granted, exercise prices, vesting schedules, and related terms. The document references compliance with listing rules and provides definitions related to the share plan. It is a regulatory announcement about equity compensation grants to employees, not a financial report, earnings release, or management discussion. It does not contain financial statements or results, nor is it a notice of voting results or a proxy statement. The document length is about 3,491 characters, which is typical for a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2023-11-17 Chinese
百济神州有限公司关于公司为子公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for its subsidiary's credit facility. It includes details about the guarantee amount, the subsidiary's financials, board approval, and opinions from sponsoring institutions. The document is a formal announcement of a corporate action (providing a guarantee) rather than a financial report or detailed management discussion. It does not contain financial statements or earnings data but focuses on a specific corporate guarantee event. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-13 Chinese
百济神州有限公司2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on accounting standards. The report covers the third quarter period and includes unaudited financial statements. The presence of comprehensive financial data for a period shorter than a full fiscal year, along with management assurances about the accuracy and completeness of the report, clearly identifies this as an Interim / Quarterly Report. The document length is over 12,000 characters and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. 9M 2023
2023-11-13 Chinese
百济神州有限公司关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from BeiGene Ltd. regarding the use of a portion of over-raised funds to permanently supplement working capital. It details the board's approval, regulatory compliance references, the amount and purpose of the funds, and includes verification opinions from joint sponsors. The document does not contain financial statements or detailed financial performance data but rather focuses on the company's capital usage decision and regulatory compliance. It is a formal disclosure about capital use, not a full financial report or earnings release. Given the content and length (3353 characters), it fits best as a Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the capital use decision itself.
2023-11-13 Chinese
中国国际金融股份有限公司、高盛（中国）证券有限责任公司关于百济神州有限公司使用部分超募资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from joint sponsors (China International Capital Corporation and Goldman Sachs China) regarding the use of part of the over-raised funds by BeiGene Ltd. to permanently supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the fundraising amount, usage plans, and confirms compliance with relevant laws and regulations. The document is not a full financial report but a specialized audit or verification opinion related to fundraising and fund usage compliance. It is not an announcement of a report publication, nor a general regulatory filing. The content aligns with an Audit Report / Information type, as it involves an audit verification opinion on the use of raised funds, including compliance with regulatory requirements and internal controls. FY 2023
2023-11-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.